Browsing "1. College of Medicine (의과대학)" by Author : 1658

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 40 of 40

This table browses all dspace content
Issue DateTitleJournal Title
2022A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY
2023Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP CANCER MEDICINE
2018Can We Prevent Resistance to Osimertinib? Combination or SequentialJOURNAL OF THORACIC ONCOLOGY
2013Changing treatment patterns in elderly patients with resectable colon cancerASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
2023Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) EUROPEAN JOURNAL OF CANCER
2014Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma Thesis
2014Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinomaLUNG CANCER
2022Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinomaJOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
2023Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2022Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study GroupTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2017Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcomaAPMIS
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2023Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer CANCER RESEARCH AND TREATMENT
2013FOXP3 Expression Is Related to High Ki-67 Index and Poor Prognosis in Lymph Node-Positive Breast Cancer PatientsONCOLOGY
2023Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer SCIENTIFIC REPORTS
2021Genomic landscape of extraordinary responses in metastatic breast cancer COMMUNICATIONS BIOLOGY
2014Ifosfamide-induced Fanconi syndrome with diabetes insipidus KOREAN JOURNAL OF INTERNAL MEDICINE
2019Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial Cancer Research and Treatment
2014Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutationsLUNG CANCER
2023Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA NATURE COMMUNICATIONS
2020Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and OlderBREAST CANCER RESEARCH AND TREATMENT
2019Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric CancerONCOLOGIST
2019MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven CancersCANCER RESEARCH
2021Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade ResponsesHEPATOLOGY
2022Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer CANCERS
2020Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response BRITISH JOURNAL OF CANCER
2023On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates BREAST CANCER RESEARCH
2020Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT
2023Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialJAMA NETWORK OPEN
2022Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)BREAST
2022Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study JOURNAL OF BONE ONCOLOGY
2022PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03ANNALS OF ONCOLOGY
2022PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroupANNALS OF ONCOLOGY
2021Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer FRONTIERS IN ONCOLOGY
2021Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial JAMA ONCOLOGY
2019Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer EMBO MOLECULAR MEDICINE
2022Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2023Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)LANCET GASTROENTEROLOGY & HEPATOLOGY
2012신장 재이식 환자의 다발성 내장 침범 카포시육종에서 Sirolimus 치료를 통한 부분 관해 및 이식신 보존 1예 Journal of the Korean Society for Transplantation
1

Browse

Links